help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mandarino, L.
Right arrow Articles by Rizza, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mandarino, L.
Right arrow Articles by Rizza, R.

Journal of Clinical Endocrinology & Metabolism, Vol 59, 658-664, Copyright © 1984 by Endocrine Society


ARTICLES

Mechanism of hyperglycemia and response to treatment with an inhibitor of fatty acid oxidation in a patient with insulin resistance due to antiinsulin receptor antibodies

L Mandarino, E Tsalikian, S Bartold, H Marsh, A Carney, E Buerklin, G Tutwiler, M Haymond, B Handwerger and R Rizza

Severe hyperglycemia and insulin resistance due to antiinsulin receptor antibodies developed over a period of 3 months in a 50-yr-old insulin- requiring diabetic patient. The hyperglycemia resulted from overproduction of glucose due to excessive rates of glycogenolysis and gluconeogenesis rather than decreased glucose utilization. Treatment with methyl-2-tetradecylglycidate, an inhibitor of fatty acid oxidation, resulted in a decrease in plasma glucose concentration. This was associated with a decrease in the rate of glucose production due to decreases in both gluconeogenesis and glycogenolysis rates, as well as an increase in the respiratory quotient. Plasma glucose concentrations continued to respond to the drug for the next 2 months until the sudden development of terminal hypoglycemia. The hypoglycemic action of the drug is consistent with the existence of an insulin-independent effect of fatty acid oxidation on glucose metabolism in man.


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
I. Duivenvoorden, B. Teusink, P. C. N. Rensen, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol
Acute inhibition of hepatic {beta}-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity
J. Lipid Res., May 1, 2005; 46(5): 988 - 993.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. O. Deems, R. C. Anderson, and J. E. Foley
Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1998; 274(2): R524 - R528.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society